CCL2 and metabolic dysfunction-associated steatohepatitis: It is thus likely that disease pathways other than MCP-1/CCR2 become upregulated at later stages of disease process (e.g. RANTES/CCR5) and that interventions merely targeting MCP-1/CCR2 become less efficient in treating NASH.